Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-09-10 02:02 UTC

BIOMED PULSE

September 10, 2026 | Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Bundibugyo virus (Ebola) outbreak in the Democratic Republic of the Congo has now spread to 60 health zones across 6 provinces, making it the largest Ebola outbreak ever recorded in that country and still accelerating. [1] Mood: urgent on outbreak front, cautiously active on longevity science.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS DISEASE (EBOLA) — DRC & UGANDA: RECORD-BREAKING OUTBREAK

  • As of August 28, 2026, the Bundibugyo virus disease (BVD) outbreak has reached 60 health zones, up from 54 at the previous report, spanning 6 of 26 DRC provinces: Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo. [1]
  • The outbreak is now formally described by WHO as the largest Ebola outbreak ever reported in the DRC, expanding faster than any previous Ebola outbreak, with sustained transmission as its defining character. [2]
  • As of July 15, 2026, cumulative confirmed cases stood at 2,124 with 828 deaths (case fatality rate approximately 39%) from the DRC alone; cross-border transmission to Uganda has been documented throughout. [3]
  • The outbreak originated in Mongbwalu Health Zone, Ituri Province, first flagged to WHO on May 5, 2026 as a high-mortality unknown illness with deaths among health workers, and Bundibugyo virus was confirmed by the Institut national de recherche biomédicale (INRB) on May 14, 2026. [4]
  • Six additional health zones reported new cases in the most recent reporting window, signaling continued geographic expansion with no containment plateau yet visible. [1]
  • CDC mobilized an international response starting May 17, 2026, and enhanced Ebola airport screening has been active at Washington-Dulles International Airport and Atlanta. [5] [6]

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • The Andes hantavirus (ANDV) outbreak linked to the cruise ship M/V Hondius, first reported to WHO on May 2, 2026, has been covered in five WHO Disease Outbreak News reports as of July 2, 2026; the ship originally carried 147 passengers and crew plus 34 who had previously disembarked. [7]
  • Two additional confirmed cases were noted between the third and fourth DON updates (May 13 to May 28, 2026); CDC provided hantavirus response transcripts through at least June 24, 2026. [8] [9]
  • Andes hantavirus causes hantavirus cardiopulmonary syndrome (HCPS), a severe respiratory illness with high fatality; person-to-person transmission of ANDV is documented and distinguishes it from most other hantavirus strains. [10]

NIPAH VIRUS — INDIA

  • On June 11, 2026, Kerala State Health Department confirmed one laboratory case of Nipah virus (NiV) in an adult male in Kozhikode district; he developed neurological symptoms on May 30, 2026 and was hospitalized June 10, 2026.
  • This is a recurring hotspot: Kozhikode district has seen prior NiV events; WHO is monitoring for secondary cases given NiV's person-to-person transmission potential.

MEASLES — BANGLADESH

  • WHO notified of a nationwide measles surge in Bangladesh affecting 58 of 64 districts across all 8 divisions; 19,161 suspected cases and 2,897 laboratory confirmed cases were reported as of the April 23, 2026 DON.
  • Global context: measles infected 10.3 million people worldwide in 2023 per CDC-WHO data, underscoring vaccination gaps still driving resurgent outbreaks.

AVIAN INFLUENZA A(H9N2) — ITALY

  • WHO reported a human case of avian influenza A(H9N2) in an adult male returning from Senegal, confirmed by Italy's IHR Focal Point on March 21, 2026, with next-generation sequencing confirming the subtype.
  • H9N2 is a low-pathogenicity avian influenza strain but is considered a pandemic risk candidate due to its wide circulation in poultry across Asia and Africa.

YELLOW FEVER — GLOBAL

  • From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections; elevated transmission activity that began in the Americas in 2025 has carried into 2026.

SALMONELLA — METABOLIC MEALS HOME DELIVERY

  • As of September 5, 2026, 16 people in 10 states have fallen ill with the same Salmonella strain linked to certain Metabolic Meals home delivery products; investigation is active.

DRUG-RESISTANT BACTERIA — CDC REPORT

  • A CDC report released September 23, 2025 found a dramatic increase in dangerous drug-resistant bacteria in the U.S., raising alarm about the antimicrobial resistance pipeline.

CONGENITAL SYPHILIS — U.S.

  • New CDC data (September 24, 2025) show U.S. cases of syphilis in newborns increased for the 12th consecutive year in 2024, reflecting a sustained STI epidemic despite some prior signals of slowing.

🧬 LONGEVITY & AGING

SENESCENCE AS ENDOCRINE FAILURE: A NEW CONCEPTUAL FRAME

  • A paper in Ageing Research Reviews (Bi Z, Lin Y) proposes that cellular senescence should be understood as "endocrine information failure in aging" — meaning that senescent cells disrupt the chemical signaling networks that coordinate organ function across the body, not merely causing local damage.
  • This reframing has practical implications: therapies may need to restore systemic communication networks, not just clear individual senescent cells.

PARP-1 INHIBITION SLOWS OSTEOARTHRITIS BY QUIETING SENESCENT CHONDROCYTES

  • Zhang R et al. (Cell Signal, published August 22, 2026) show that inhibiting PARP-1 — a DNA-damage repair enzyme — attenuates osteoarthritis progression by suppressing NF-kB inflammatory signaling and alleviating senescence in chondrocytes, the cartilage cells that degrade in OA.
  • PARP inhibitors are already FDA-approved for certain cancers, raising interest in repurposing potential for joint disease.

SENESCENCE-TARGETING EXTRACELLULAR VESICLES FOR DISC DEGENERATION

  • Shi P et al. (Biomaterials, July 14, 2026) engineered senescence-targeting apoptotic extracellular vesicles loaded into injectable hydrogel microspheres; the system mitigates ferroptosis (an iron-dependent cell death pathway) in nucleus pulposus cells and counteracts intervertebral disc degeneration in preclinical models.
  • This combines two cutting-edge aging-biology tools — senolytics and ferroptosis suppression — in a single injectable format targeting the spine.

DUAL ANTIOXIDANT-EPIGENETIC THERAPY BREAKS THE SENESCENCE CYCLE IN JOINTS

  • An X et al. (Bioactive Materials, July 31, 2026) demonstrate that combining antioxidant action with epigenetic reprogramming synergistically interrupts the self-perpetuating senescence cycle in osteoarthritis, where senescent cells trigger more senescence in neighboring cells via the SASP (senescence-associated secretory phenotype).

EGFR LOSS IN SKELETAL STEM CELLS IMPAIRS FRACTURE HEALING WITH AGE

  • Hu Y et al. (Bioactive Materials, August 4, 2026) find that loss of EGFR (epidermal growth factor receptor) activity in skeletal stem/progenitor cells is directly associated with impaired fracture healing in aged mice, identifying a targetable molecular mechanism for the well-known clinical problem of slower bone repair in older patients.

MRNA NANOPARTICLE RESTORES CHOLESTEROL HOMEOSTASIS FOR AGE-RELATED BONE DEFECTS

  • Cheng M et al. (Bioactive Materials, August 20, 2026) describe a dual-targeting mRNA lipid nanoparticle that restores ABCA1-dependent cholesterol transport in aging bone, promoting repair of age-related bone defects in animal models — an early but notable convergence of mRNA delivery technology and geroscience.

TESTOSTERONE DEFICIENCY: INTERNATIONAL PRIMARY CARE CONSENSUS

  • David J, Morgentaler A et al. (Aging Male, August 26, 2026) published an international expert consensus on managing testosterone deficiency in primary care, involving 12 authors including clinicians from the U.S., UK, and Europe, addressing a hormonally-linked aging syndrome frequently under-diagnosed.

DEMENTIA AND CANCER INCIDENCE: SEX-SPECIFIC ECOLOGICAL LINK

  • You W et al. (Future Science OA, September 4, 2026) conducted a cross-country sex-specific ecological analysis finding patterns between cancer incidence and dementia incidence, suggesting shared or competing biological pathways that may affect both conditions differently in men versus women.

SPINAL VS. GENERAL ANAESTHESIA FOR HIP FRACTURE IN OLDER PATIENTS

  • Kowark A et al. (Lancet Healthy Longevity) present results from a multicentre randomised clinical trial in Germany comparing spinal versus general anaesthesia for hip fracture surgery in older patients, with serious complications as the primary endpoint — directly relevant to peri-operative care in aging populations.

DEPRESCRIBING TRIALS NEED RATIONALE-FIRST FRAMEWORK

  • Hwang CS, Boockvar KS, Steinman MA (Lancet Healthy Longevity) argue that deprescribing trials — testing whether stopping medications in older adults is beneficial — require a rationale-first framework before selecting trial design, addressing a critical gap in polypharmacy management in aging.

💊 NEW CURES & APPROVALS

ZANVASTRO (ZILGANERSEN) — IONIS PHARMACEUTICALS

  • Ionis Pharmaceuticals received an original FDA approval (NDA220210) for Zanvastro, the brand name for zilganersen, marking a notable addition to the CNS-targeting antisense oligonucleotide drug class from the developer of that platform.

AVTOZMA (TOCILIZUMAB-ANOH) — CELLTRION INC.

  • Celltrion received supplemental approvals on two BLA applications (BLA761498 and BLA761420) for Avtozma, the biosimilar tocilizumab-anoh, an IL-6 receptor antagonist used in rheumatoid arthritis, systemic JIA, giant cell arteritis, and cytokine release syndrome.

FYARRO (SIROLIMUS) — AADI

  • AADI received a supplemental approval (NDA213312) for Fyarro, an albumin-bound sirolimus (mTOR inhibitor) formulation; original approval was for malignant perivascular epithelioid cell tumor (PEComa).

RELUGOLIX — SANDOZ INC.

  • Sandoz received an original tentative approval (ANDA219913) for a generic relugolix, a GnRH receptor antagonist used in advanced prostate cancer and uterine fibroids, broadening access to the class.

CIBINQO (ABROCITINIB) — PFIZER

  • Pfizer received a supplemental approval (NDA213871) for Cibinqo (abrocitinib), a JAK1 inhibitor approved for moderate-to-severe atopic dermatitis.

SACUBITRIL/VALSARTAN — AUROBINDO PHARMA LTD.

  • Aurobindo Pharma received an original generic approval (ANDA213631) for sacubitril/valsartan, the heart failure combination drug (original brand: Entresto), expanding the affordable generic supply for an HFrEF indication.

DAPAGLIFLOZIN — AJANTA PHARMA LTD.

  • Ajanta Pharma received a supplemental approval (ANDA211482) for generic dapagliflozin, an SGLT2 inhibitor with approvals spanning type 2 diabetes, heart failure, and chronic kidney disease.

ALENDRONATE SODIUM — PRECISION DOSE INC.

  • Precision Dose received an original generic approval (ANDA214523) for alendronate sodium, a bisphosphonate used to treat and prevent osteoporosis — relevant to aging bone health.

🧪 CLINICAL TRIALS

BPL-1357 UNIVERSAL INFLUENZA CANDIDATE — NIH/NIAID, PHASE I CHALLENGE STUDY

  • ClinicalTrials.gov (NCT07215858, registered September 9, 2026) is evaluating BPL-1357 against live H1N1 influenza virus challenge; the trial is designed to test broader vaccine protection that could address pandemic strains, not just seasonal flu.
  • Background: 3–5 million severe influenza cases and up to 500,000 deaths occur annually worldwide, and existing vaccines provide limited pandemic coverage.

[18F]3F4AP PET IMAGING FOR DEMYELINATION — ALZHEIMER'S, MS, SCI

  • NCT06999434 (registered September 9, 2026) is assessing the pharmacokinetics of the radiotracer [18F]3F4AP in healthy volunteers and subjects with mild cognitive impairment, Alzheimer's disease, multiple sclerosis, spinal cord injury, and spinal radiculopathy — aiming to develop a universal demyelination imaging biomarker.

B7-H3 CAR-T CELLS IN SMALL CELL LUNG CANCER

  • NCT07509034 (registered September 9, 2026) is studying autologous B7-H3 chimeric antigen receptor T cells in patients with previously treated extensive-stage SCLC or extrapulmonary neuroendocrine cancer; B7-H3 is widely expressed on these highly lethal tumor cells.

WEARABLE SLEEP EEG WITH AUDITORY STIMULATION — HEALTHY ADULTS

  • NCT07808645 (registered September 9, 2026) is a single-site pilot evaluating a wearable device that records sleep EEG and delivers low-volume auditory stimulation during targeted sleep stages in approximately 30 healthy adults; pilot data could inform slow-wave sleep enhancement strategies linked to memory consolidation and brain waste clearance relevant to aging.

INTERACTIVE EXERGAME WALL FOR NURSING HOME RESIDENTS — FRANCE

  • NCT07809087 (registered September 9, 2026) is a 12-week feasibility study of the Mur'Aventure immersive exergame wall program in older adults in French EHPADs (nursing homes) and long-term care units, targeting physical activity and functional engagement in frail elderly populations.

MIRABEGRON + ALPHA-LIPOIC ACID FOR OBESITY — NIH

  • NCT05713799 is evaluating the combination of mirabegron (a beta-3 adrenergic agonist that activates brown fat) and alpha-lipoic acid (an antioxidant) in women and men with obesity; obesity affects 35% or more of adults in 23 U.S. states as of 2023.

EPA + DHA BIOAVAILABILITY FROM MICROALGAL VS. FISH SOURCES

  • NCT07241377 is a randomized double-blind parallel placebo-controlled 6-week trial comparing absorption of omega-3 fatty acids (EPA + DHA) from two microalgal formulations versus fish oil in healthy adults — relevant to sustainable longevity nutrition sourcing.

TDCS FOR LOGOPENIC VARIANT PRIMARY PROGRESSIVE APHASIA — ALZHEIMER'S-LINKED

  • NCT03887481 is targeting language-specific and executive-control brain networks with transcranial direct current stimulation (tDCS) in logopenic variant PPA, the language-dominant Alzheimer's variant; over 5.5 million Americans have AD.

NEMTABRUTINIB FOR COVALENT BTK INHIBITOR-REFRACTORY CLL/SLL

  • NCT07796373 (registered September 9, 2026) is studying nemtabrutinib — a non-covalent BTK inhibitor — in chronic lymphocytic leukemia/small lymphocytic leukemia patients refractory to both covalent BTKi (e.g., ibrutinib) and pirtobrutinib, and previously treated with a BCL2 inhibitor; this represents a heavily pre-treated, high-unmet-need aging blood cancer population.

📢 PUBLIC HEALTH

SALMONELLA — RECALLED EGGS, 95 CASES IN 14 STATES

  • As of August 28, 2026, 95 people across 14 states have been sickened by the same Salmonella strain linked to recalled eggs; CDC urges consumers to check and discard any recalled product.

LISTERIA — EXPANDED PREPARED FOODS OUTBREAK

  • CDC expanded a Listeria monocytogenes outbreak alert to include additional prepared meals as of September 26, 2025; 3 additional illnesses and 1 additional death were reported in the expansion update; consumers are urged to check refrigerators and freezers.

CYCLOSPORA — TACO BELL SHREDDED ICEBERG LETTUCE, 1,644 SICK IN 9+ STATES

  • As of July 24, 2026, the Cyclospora outbreak linked to shredded iceberg lettuce served at Taco Bell locations had expanded to four additional states; CDC first identified the source on July 17, 2026 with 1,644 cases across 5 states at that point.

E. COLI — FROZEN BLUEBERRIES RECALL ACTIVE

  • CDC issued a food safety alert on July 7, 2026 warning of an E. coli outbreak linked to recalled frozen blueberries; consumers are advised not to eat recalled product.

WEST NILE VIRUS — EARLY SEASON WITH RECORD CASES

  • CDC flagged early in the 2026 summer season that West Nile virus was showing record early case counts; mosquito bite prevention was urged during the July 4th holiday weekend.

WEST NILE AND TICK-BORNE DISEASE SURVEILLANCE

  • CDC data released April 23, 2026 showed weekly emergency room visits for tick bites higher than usual for the season; public health resources for tick protection were highlighted.

TIMOR-LESTE CERTIFIED MALARIA-FREE BY WHO

  • WHO certified Timor-Leste as malaria-free on July 23, 2025, recognizing a nationwide elimination program launched shortly after independence in 2002 — a landmark achievement for a low-income nation.

KINDERGARTEN VACCINATION RATES

  • CDC data released August 17, 2026 show kindergarten vaccination rates remain high nationally, with a slight 0.1% decline in coverage — a signal to watch given ongoing measles pressure globally.

This edition of BIOMED PULSE is informational only and does not constitute medical advice. Consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  5. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  6. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  7. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  8. Hantavirus cluster linked to cruise ship travel, Multi-country — WHO Disease Outbreak News
  9. Transcript - Update on CDC's Hantavirus Response - 6/24/26 — CDC Newsroom
  10. Hantavirus cluster linked to cruise ship travel, Multi-country — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260910-02-v71 · 2026-09-10 02:02 UTC · pulse.uzylab.com

Read next